The company sold 2.2 million shares at an average price of $22.73 per share under a $50 million at-the-market equity facility it filed in March 2019.
The firm plans to use the funds raised to support business activities, as it moves forward in the development of cancer early detection tests.
The Australian firm will use the proceeds for R&D, expansion in China, and to fund the development of polygenic risk tests with TGen in the US.
The firm said that it may use some of the net proceeds to acquire or invest in complementary businesses and technologies.
The company estimated that the offering could raise between $327.2 and $376.3 million, which it would use for various corporate purposes.
The company, based in Fort Myers, Florida, said that it plans to use the net proceeds from the offering for general corporate purposes.
The firm sold 4.31 million shares after the underwriters fully exercised their options to purchase 562,500 shares at the offering price of $21 per share.
The company will offer 3.75 million shares of its common stock at $21 per share.
The company will use the proceeds to expand its R&D capabilities and its commercial operations.
The company plans to offer 5.5 million shares of its common stock at $23.25 per share, raising around $127.9 million.
Mainichi reports that 43 percent of Japanese individuals said they did not want to eat agricultural products that had been modified using gene-editing tools.
Two US Department of Agriculture research departments are moving to the Kansas City area, according to the Washington Post.
Slate's Jane Hu compares some at-home genetic tests to astrology.
US National Institutes of Health Director Francis Collins says he will avoid male-only speaker panels.